Literature DB >> 27896668

Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide.

Xiaoxuan Liu1, Lin Zhu1, Jingjing Ma1, Xinxiao Qiao1, Dunwan Zhu1, Lanxia Liu2, Xigang Leng3.   

Abstract

RNA interference (RNAi) is among the most potential approach for the therapy of hepatocellular carcinoma and the major barrier hindering siRNA therapeutics is the low efficiency of delivery to the desired cells. The current study aimed at developing a novel peptide for more efficient hepatoma targeted siRNA delivery, by combining luteinizing hormone-releasing hormone with hepatoma targeting specificity and MPG△NLS with cytoplasm-delivery tendency. The developed bifunctional peptide LHRH-MPG△NLS and siRNA were mixed together and resulted in LHRH-MPG△NLS/siRNA polyplexes through self-assembly. The polyplexes were characterized by agarose gel retardation and dynamic light scatting analysis. Hepatoma targeting specificity was analyzed with the GE IN Cell Analyzer 2000 High-Content Cellular Analysis System after cell transfection, and the effect of RNA interference was detected by RT-PCR. The results demonstrated that LHRH-MPG△NLS was able to assemble with siRNA to form stable and nano-sized peptide/siRNA polyplexes, which could inhibit the expression of the target gene and was essentially non-cytotoxic, as compared with the commercial transfection reagent lipofectamine 2000.

Entities:  

Keywords:  Cancer therapy; Hepatoma; LHRH-MPG△NLS; siRNA delivery

Mesh:

Substances:

Year:  2017        PMID: 27896668     DOI: 10.1007/s13346-016-0348-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  36 in total

1.  Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells.

Authors:  Federica Simeoni; May C Morris; Frederic Heitz; Gilles Divita
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

Review 2.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

Review 3.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 4.  RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases.

Authors:  Agueda Gonzalez-Rodriguez; Angela M Valverde
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

5.  Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.

Authors:  Kathrin Klutz; David Schaffert; Michael J Willhauck; Geoffrey K Grünwald; Rudolf Haase; Nathalie Wunderlich; Christian Zach; Franz J Gildehaus; Reingard Senekowitsch-Schmidtke; Burkhard Göke; Ernst Wagner; Manfred Ogris; Christine Spitzweg
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

6.  Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.

Authors:  S S Dharap; B Qiu; G C Williams; P Sinko; S Stein; T Minko
Journal:  J Control Release       Date:  2003-08-28       Impact factor: 9.776

7.  Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.

Authors:  Ming-Rong Cheng; Qing Li; Tao Wan; Bing He; Jiang Han; Hou-Xiang Chen; Feng-Xiao Yang; Wei Wang; Hong-Zhi Xu; Tao Ye; Bing-Bing Zha
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

8.  Development of cholesteryl peptide micelles for siRNA delivery.

Authors:  Bin Qin; Zhijin Chen; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2013-08-19       Impact factor: 9.776

9.  Adenovirus-delivered CIAPIN1 small interfering RNA inhibits HCC growth in vitro and in vivo.

Authors:  Xiaohua Li; Yanglin Pan; Rui Fan; Haifeng Jin; Shuang Han; Jie Liu; Kaichun Wu; Daiming Fan
Journal:  Carcinogenesis       Date:  2008-02-24       Impact factor: 4.944

Review 10.  Challenges of advanced hepatocellular carcinoma.

Authors:  Stefano Colagrande; Andrea L Inghilesi; Sami Aburas; Gian G Taliani; Cosimo Nardi; Fabio Marra
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

View more
  1 in total

Review 1.  Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.

Authors:  Deidra M Ward; Aaliyah B Shodeinde; Nicholas A Peppas
Journal:  Adv Healthc Mater       Date:  2021-05-11       Impact factor: 11.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.